BioCentury | Apr 15, 2013
Company News

ImmuLogic board of directors update

ImmuLogic Pharmaceutical Corp. (IMUL), Waltham, Mass. Business: Autoimmune/Inflammation Resigned: Malcom Gefter, Ph.D., company founder; and, Alan Dalby, Howard Jacobson, Kenneth Melmon, M.D., Larry Soll, Ph.D. Appointed: Joseph Marr, M.D., acting president and CEO; Garrison Fathman,...
BioCentury | Apr 15, 2013
Company News

ProScript management update

...Hired: Stacey Channing, as VP, patent and legal counsel; formerly VP and general counsel for ImmuLogic Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Company News

ImmuLogic autoimmune/inflammation news

...a trial of Allevax Ragweed this summer, while continuing work on the cat allergy product. ImmuLogic Pharmaceutical Corp....
BioCentury | Jan 20, 2003
Finance

Ebb & Flow

...rights to TA-CD and TA-NIC vaccines to treat cocaine addiction and nicotine addiction, respectively, from ImmuLogic's...
BioCentury | Jan 20, 2003
Company News

ImmuLogic, Xenova deal

...buy back remaining milestone and royalty rights to TA-CD and TA-NIC drug addiction vaccines from ImmuLogic's...
...1998 deal, Cantab Pharmaceuticals plc , (Cambridge, U.K.), which merged with XEN in 2001, acquired ImmuLogic's...
...to cholera toxin B subunit, is in a Phase I trial to treat nicotine addiction. ImmuLogic...
BioCentury | Jan 15, 2003
Company News

Xenova buys back vaccine rights

...buy back remaining milestone and royalty rights to TA-CD and TA-NIC drug addiction vaccines from ImmuLogic's...
...liquidation trust. Under a 1998 deal, Cantab Pharmaceuticals, which merged with XEN in 2001, acquired ImmuLogic's...
...to cholera toxin B subunit, is in a Phase I trial to treat nicotine addiction. ImmuLogic...
BioCentury | Jul 1, 2002
Finance

2Q Financial Markets Review: Hard decisions loom

...folding up the tent and giving back money to their shareholders, as he coached ImmuLogic Pharmaceutical Corp....
...do in 1999. "When I was at H&Q with Dennis Purcell, we got hired by ImmuLogic...
...cash, then let's give it back to the shareholders and let them decide." In 1999, ImmuLogic's...
BioCentury | Sep 7, 1999
Strategy

Back to School 1999: Structure 2000

...$651.20 Igen (IGEN) $86.80 $74.80 $201.40 $467.10 $392.80 ImClone (IMCL) $113.00 $196.10 $196.60 $220.20 $574.50 ImmuLogic...
...$651.20 Igen (IGEN) $86.80 $74.80 $201.40 $467.10 $392.80 ImClone (IMCL) $113.00 $196.10 $196.60 $220.20 $574.50 ImmuLogic...
BioCentury | Aug 30, 1999
Company News

ImmuLogic autoimmune/inflammation news

...operations because of contingencies and lack of specifics in the proposal (see BioCentury, Aug. 23). ImmuLogic Pharmaceutical Corp....
BioCentury | Aug 23, 1999
Company News

ImmuLogic autoimmune/inflammation news

...operations. Earlier this year, IMUL's board voted to liquidate the company (see BioCentury, April 5). ImmuLogic Pharmaceutical Corp....
Items per page:
1 - 10 of 90
BioCentury | Apr 15, 2013
Company News

ImmuLogic board of directors update

ImmuLogic Pharmaceutical Corp. (IMUL), Waltham, Mass. Business: Autoimmune/Inflammation Resigned: Malcom Gefter, Ph.D., company founder; and, Alan Dalby, Howard Jacobson, Kenneth Melmon, M.D., Larry Soll, Ph.D. Appointed: Joseph Marr, M.D., acting president and CEO; Garrison Fathman,...
BioCentury | Apr 15, 2013
Company News

ProScript management update

...Hired: Stacey Channing, as VP, patent and legal counsel; formerly VP and general counsel for ImmuLogic Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Company News

ImmuLogic autoimmune/inflammation news

...a trial of Allevax Ragweed this summer, while continuing work on the cat allergy product. ImmuLogic Pharmaceutical Corp....
BioCentury | Jan 20, 2003
Finance

Ebb & Flow

...rights to TA-CD and TA-NIC vaccines to treat cocaine addiction and nicotine addiction, respectively, from ImmuLogic's...
BioCentury | Jan 20, 2003
Company News

ImmuLogic, Xenova deal

...buy back remaining milestone and royalty rights to TA-CD and TA-NIC drug addiction vaccines from ImmuLogic's...
...1998 deal, Cantab Pharmaceuticals plc , (Cambridge, U.K.), which merged with XEN in 2001, acquired ImmuLogic's...
...to cholera toxin B subunit, is in a Phase I trial to treat nicotine addiction. ImmuLogic...
BioCentury | Jan 15, 2003
Company News

Xenova buys back vaccine rights

...buy back remaining milestone and royalty rights to TA-CD and TA-NIC drug addiction vaccines from ImmuLogic's...
...liquidation trust. Under a 1998 deal, Cantab Pharmaceuticals, which merged with XEN in 2001, acquired ImmuLogic's...
...to cholera toxin B subunit, is in a Phase I trial to treat nicotine addiction. ImmuLogic...
BioCentury | Jul 1, 2002
Finance

2Q Financial Markets Review: Hard decisions loom

...folding up the tent and giving back money to their shareholders, as he coached ImmuLogic Pharmaceutical Corp....
...do in 1999. "When I was at H&Q with Dennis Purcell, we got hired by ImmuLogic...
...cash, then let's give it back to the shareholders and let them decide." In 1999, ImmuLogic's...
BioCentury | Sep 7, 1999
Strategy

Back to School 1999: Structure 2000

...$651.20 Igen (IGEN) $86.80 $74.80 $201.40 $467.10 $392.80 ImClone (IMCL) $113.00 $196.10 $196.60 $220.20 $574.50 ImmuLogic...
...$651.20 Igen (IGEN) $86.80 $74.80 $201.40 $467.10 $392.80 ImClone (IMCL) $113.00 $196.10 $196.60 $220.20 $574.50 ImmuLogic...
BioCentury | Aug 30, 1999
Company News

ImmuLogic autoimmune/inflammation news

...operations because of contingencies and lack of specifics in the proposal (see BioCentury, Aug. 23). ImmuLogic Pharmaceutical Corp....
BioCentury | Aug 23, 1999
Company News

ImmuLogic autoimmune/inflammation news

...operations. Earlier this year, IMUL's board voted to liquidate the company (see BioCentury, April 5). ImmuLogic Pharmaceutical Corp....
Items per page:
1 - 10 of 90